BMO Capital analyst Evan Seigerman maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $480 to $500.
BMO Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $500
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.